Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations (NCT07581379)
Protocol for an Observational Cohort Study Integrating Real-World Data and Microsimulation to Assess Imaging Surveillance Strategies in Stage I-IIIA NSCLC Patients in OneFlorida+
🩺 Plain-English Summary (8th-Grade Level)
This observational study evaluates the effectiveness of computed tomography (CT) imaging surveillance after curative-intent treatment for stage I-IIIA non-small cell lung cancer (NSCLC) in a diverse U.S. population. The main questions are: How do CT surveillance use and adherence vary by race, ethnicity, and socioeconomic status? Does semi-annual CT surveillance improve outcomes compared with annual surveillance? Adults ages 20-90 with stage I-IIIA NSCLC treated between 2012 and 2026 will be identified using OneFlorida+ electronic health records, tumor registry data, claims, and clinical notes. Patients will be followed for up to five years after curative-intent therapy to evaluate surveillance patterns, recurrence, second primary lung cancers, complications, and survival.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (9 items).
Location: University of Florida College of Medicine — Gainesville, Florida
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Histology other than NSCLC, including: Small-cell lung cancer Carcinoid tumors Rare non-NSCLC primary tumors
- Metastatic disease (stage IV) at diagnosis.
- No curative-intent therapy received (e.g., palliative treatment only).
- Patients with incomplete treatment records prevent the determination of the treatment completion date.
- Patients with no surveillance-relevant follow-up data, including: No post-treatment clinical notes No radiology/pathology records No linked tumor registry or vital status data
- Patients with recurrence or who die within the first 5 months after starting curative-intent therapy (insufficient window for guideline-defined surveillance).
- Patients with missing identifiers prevent linkage to cancer registries or the death index.
- Individuals whose imaging cannot be classified as surveillance vs. diagnostic due to the absence of relevant structured or unstructured data.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- University of Florida College of Medicine — Gainesville, Florida
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Neoplasms
- Specimen Banking From Patients With Lung Cancer — Aurora, Colorado
- TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics — New Brunswick, New Jersey
- TELESCOPE- TELEhealth Shared Decision-making COaching — New Brunswick, New Jersey
- LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada — Calgary, Alberta
- A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer — Jacksonville, Florida
Explore by condition: All Lung Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.